Temporal lobe epilepsy (TLE) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Temporal lobe epilepsy (TLE) is the most common form of focal epilepsy in adults, characterized by recurrent seizures originating from the temporal lobe. TLE is often associated with hippocampal sclerosis and represents a significant neurological condition with bidirectional relationships to neurodegenerative processes. The disease affects approximately 1-2% of the general population, with TLE accounting for roughly 30-40% of all epilepsies and 60% of drug-resistant epilepsies.
The temporal lobe comprises both mesial (medial) and lateral (neocortical) structures, each capable of generating seizures with distinct clinical characteristics. Mesial temporal lobe epilepsy (MTLE), the most common subtype, typically involves the hippocampus, amygdala, and parahippocampal gyrus, and is frequently associated with hippocampal sclerosis - a hallmark pathological finding characterized by neuronal loss and gliosis. Lateral temporal lobe epilepsy (LTLE), while less common, often arises from structural lesions and may present with auditory or language-related symptoms.
TLE has emerged as a critical area of intersection between epileptology and neurodegenerative disease research. The bidirectional relationship between TLE and conditions such as Alzheimer's disease (AD), Parkinson's disease (PD), and other neurodegenerative disorders has become increasingly evident. Patients with TLE show higher rates of cognitive decline and demonstrate pathological hallmarks of neurodegenerative diseases, while individuals with neurodegenerative conditions exhibit elevated seizure incidence.
Mesial temporal lobe epilepsy represents the most common and clinically significant form of TLE:
- Originates from medial temporal structures including the hippocampus, amygdala, and parahippocampal gyrus
- The most common subtype, accounting for approximately 70-80% of TLE cases
- Frequently drug-resistant, with only 30-40% achieving seizure freedom with medication alone
- Strongly associated with hippocampal sclerosis, present in 60-70% of MTLE patients
- Characterized by auras (warnings), typically epigastric rising sensation, déjà vu, or olfactory/gustatory hallucinations
Lateral temporal lobe epilepsy arises from the neocortical portions of the temporal lobe:
- Originates from the superior, middle, and inferior temporal gyri
- Less common than MTLE, representing approximately 20-30% of TLE cases
- Frequently associated with structural lesions including cortical dysplasia, tumors, or vascular malformations
- Presents with auditory manifestations (sounds, music), language difficulties (if dominant hemisphere), or visual misperceptions
Hippocampal sclerosis (HS) is the most common pathological finding in MTLE:
Classic (Ammon's horn) sclerosis:
- Severe neuronal loss in CA1 region (Sommer's sector)
- Moderate loss in CA3 and CA2 regions
- Relative preservation of CA4 and dentate granule cells
- Proliferation of astroglial cells (gliosis)
- Often unilateral, predominantly affecting the left hemisphere
Granule cell dispersion:
- Abnormal migration and increased spacing of dentate granule cells
Mossy fiber sprouting:
- Axonal reorganization of dentate granule cells
- Forms new synaptic connections in inner molecular layer
- May contribute to hyperexcitability
Excitotoxicity represents a fundamental mechanism of seizure-induced neuronal damage:
- Glutamate receptor overactivation: Excessive stimulation of NMDA and AMPA receptors leads to calcium influx
- Intracellular calcium dysregulation: Activates enzymatic degradation of cellular components
- Mitochondrial dysfunction: Impaired energy production and release of pro-apoptotic factors
- Oxidative stress: Generation of reactive oxygen species damaging cellular components
Inhibitory system dysfunction contributes to network hyperexcitability:
- Inhibitory neuron loss: Specific populations of GABAergic interneurons are selectively vulnerable
- Reduced GABA synthesis: Decreased glutamic acid decarboxylase (GAD) activity
- Impaired receptor function: Altered GABA-A receptor subunit composition
Neuroinflammatory processes play a critical role in TLE pathogenesis:
- Microglial activation: Persistent elevation of pro-inflammatory cytokines (IL-1β, TNF-α, IL-6)
- Astrocytic dysfunction: Impaired potassium buffering and glutamate uptake
- Blood-brain barrier disruption: Allows peripheral immune cell infiltration
Beyond the hippocampus, broader network changes contribute to TLE:
- Entorhinal cortex dysfunction: Primary gateway for hippocampal input/output
- Thalamic involvement: Second-order relay structures become hyperactive
- Cortical connectivity: Aberrant connections to frontal and parietal lobes
Auras represent the initial subjective experience of a focal seizure:
- Epigastric rising sensation: Most common mesial aura; nausea, butterflies, rising sensation from abdomen to chest
- Fear and anxiety: Intense, inexplicable feelings of dread or terror
- Olfactory/gustatory hallucinations: Unpleasant smells or tastes
- Auditory phenomena: Sounds, music, or voice from lateral temporal cortex
- Autonomic symptoms: Tachycardia, palpitations, flushing, pupil dilation
- Psychic phenomena: déjà vu or jamais vu, memory flashbacks
The ictal phase encompasses the actual seizure event:
- Automotor seizures: Most common ictal pattern in MTLE; lip-smacking, chewing, swallowing, picking movements
- Dystonic posturing: Contralateral arm flexion, often with version of head and eyes
- Ocular phenomena: Nystagmus, conjugate gaze deviation
- Speech arrest: In dominant hemisphere involvement
- Consciousness impairment: From aura progression to impaired awareness
The postictal period follows the seizure:
- Confusion and disorientation: Lasts typically 5-30 minutes
- Fatigue and somnolence: Requires rest, may sleep for hours
- Headache: Common postictal symptom, may be severe
- Todd's paralysis: Transient focal weakness, typically resolves within hours
- Memory gaps: Inability to recall the seizure
EEG is essential for TLE diagnosis and localization:
Interictal (between seizures) findings:
- Temporal sharp waves: Most common interictal epileptiform discharge; anterior temporal region
- Spikes: Localized to temporal region, often enhanced during sleep
- Temporal slowing: Lateralized rhythmic delta activity, particularly during sleep
Ictal (during seizure) findings:
- Temporal rhythmic activity: Evolving frequency patterns; typically 5-10 Hz rhythmic activity
- Early spread: May propagate to contralateral temporal region or frontal lobes
- Intracranial EEG: Reserved for presurgical evaluation when surface EEG is non-localizing
MRI is critical for identifying structural causes:
Hippocampal findings:
- Atrophy: Reduced hippocampal volume on coronal T1 sequences
- T2 hyperintensity: Increased signal on T2/FLAIR sequences
- Loss of internal structure: Obliteration of hippocampal digitations
Positron emission tomography provides metabolic information:
- Hypometabolism: Most common finding; ipsilateral temporal lobe hypometabolism in 70-80% of MTLE
- Lateralization: Useful for non-dominant hemisphere focus
First-line treatment involves antiseizure medications:
| Medication |
Mechanism |
Notes |
| Levetiracetam |
SV2A modulation |
Wide efficacy, few interactions |
| Carbamazepine |
Na+ channel block |
Excellent for focal seizures |
| Valproate |
Multiple mechanisms |
Broad spectrum |
| Lamotrigine |
Na+ channel block |
Well-tolerated |
| Lacosamide |
Na+ channel enhancement |
Low interaction potential |
Treatment principles:
- Begin with single agent; titrate to maximum tolerated dose
- If first drug fails, try alternative single agent before combination
- Target seizure freedom; if not achieved, patient is drug-resistant
- 30-40% of TLE patients achieve seizure freedom with medications
Surgery is indicated for drug-resistant TLE:
Anterior temporal lobectomy (ATL):
- Standard surgical approach
- Remove anterior 3-4 cm of temporal lobe including hippocampus
- 60-70% seizure-free outcome at 5-10 years
Selective amygdalohippocampectomy (SAH):
- More selective removal of mesial structures
- May have better cognitive outcomes
Laser ablation:
- Minimally invasive approach
- MRI-guided laser destruction of hippocampus
For patients not candidates for surgery:
Vagus nerve stimulation (VNS):
- Implanted device stimulating vagus nerve
- 30-50% seizure reduction
Deep brain stimulation (DBS):
- Targets include anterior thalamic nucleus
- 40% seizure reduction at 5 years
Ketogenic diet and variants can be effective:
- Classical ketogenic diet: 4:1 ratio fat:protein+carbohydrate
- Modified Atkins diet: Less restrictive, easier to maintain
- Mechanism: Ketone bodies provide alternative fuel, alter neurotransmitter levels
The bidirectional relationship between TLE and AD has become increasingly evident:
- Increased seizure risk: AD patients have 5-10 fold increased risk of seizures compared to age-matched controls
- Shared hippocampal vulnerability: Both conditions involve hippocampal pathology
- Tau pathology: Increased tau pathology observed in TLE surgical specimens
- Accelerated cognitive decline: TLE accelerates progression to dementia
- Seizure risk: PD patients have modestly increased seizure risk
- Lewy body pathology: Found in temporal lobe of some TLE patients
- Treatment interactions: Dopaminergic medications may affect seizure threshold
TLE frequently follows traumatic brain injury (TBI):
- Post-traumatic epilepsy: 2-5% of moderate-severe TBI develop TLE
- Temporal lobe vulnerability: Particularly susceptible due to proximity to skull
- Chronic neurodegeneration: May accelerate age-related cognitive decline
TLE profoundly impacts cognitive function:
- Memory dysfunction: Episodic memory most vulnerable, particularly verbal (left TLE)
- Executive function: Impaired set-shifting and working memory
- Language deficits: Naming and word-finding difficulties in left TLE
- Psychiatric comorbidities: Depression, anxiety, and psychosis increased
- Neurofilament light chain (NfL): Elevated in serum and CSF, correlates with disease burden
- Tau protein: Elevated in TLE, correlates with cognitive impairment
- Inflammatory markers: IL-1β, TNF-α as disease activity markers
- mTOR pathway inhibitors: Everolimus, sirolimus for tuberous sclerosis-related epilepsy
- Neuroprotective agents: Targeting excitotoxicity and oxidative stress
- Anti-inflammatory approaches: IL-1 receptor antagonists, microglia modulators
- Gene therapy: Targeting ion channel dysfunction or inhibitory neurotransmission